HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Paclitaxel is effective in relapsed head and neck squamous cell carcinoma: a retrospective study of 66 patients at a single institution.

Abstract
The standard first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma is cisplatin-based chemotherapy, but taxanes can also be beneficial after progression or in patients not eligible for cisplatin. The objective of this retrospective study was to evaluate paclitaxel in this population. We reviewed 66 patients who were treated with paclitaxel at a single institution (Lyon, France) between January 2003 and November 2008. Paclitaxel was administered as first, second or more line of treatment; alone or in combination with carboplatin or cetuximab; every 3 weeks (175 mg/m(2)) or weekly (80 mg/m(2)). Forty-six (70%) patients received paclitaxel as first-line therapy after relapse and 26 (39%) patients as monotherapy. The objective response rate was 30% [95% confidence interval (CI): 20-43%]; 37% (95% CI: 23-52%) in the first line after relapse, and 20% (95% CI: 4-48%) in the second line. Rates were 19% (95% CI: 7-39%) after monotherapy and 36% (95% CI: 20-55%) after combination with carboplatin. Two of the six patients receiving cetuximab had a partial response. The overall survival of all patients was 7.2 months (95% CI: 5.2-8.8). Paclitaxel can be used in symptomatic patients. Although no improvement of overall survival can be expected, paclitaxel treatment is safe and achieves interesting response rates.
AuthorsJérôme Fayette, Anthony Montella, Sylvie Chabaud, Thomas Bachelot, Pascal Pommier, Didier Girodet, Séverine Racadot, Xavier Montbarbon, Bertrand Favier, Philippe Zrounba
JournalAnti-cancer drugs (Anticancer Drugs) Vol. 21 Issue 5 Pg. 553-8 (Jun 2010) ISSN: 1473-5741 [Electronic] England
PMID20220515 (Publication Type: Journal Article)
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Phytogenic
  • Carboplatin
  • Paclitaxel
  • Cetuximab
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal (therapeutic use)
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Phytogenic (therapeutic use)
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Carboplatin (therapeutic use)
  • Carcinoma, Squamous Cell (drug therapy)
  • Cetuximab
  • Head and Neck Neoplasms (drug therapy)
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local (drug therapy)
  • Paclitaxel (therapeutic use)
  • Retrospective Studies
  • Survival Analysis
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: